Researchers from Fred Hutchinson Cancer Center in Seattle, Scripps Research in La Jolla, California, IAVI and other collaborating institutions have characterized robust T-cell responses in volunteers participating in the ...
May 24, 2023
0
55
Researchers from the Mpox Emergency Response Team, Centers for Disease Control and Prevention (CDC) in Atlanta have conducted a case-control study based on data from a nationwide electronic health record database, Cosmos, ...
A new HIV vaccine from Scripps Research has shown a significantly improved ability to neutralize the virus in preclinical tests, and it will soon be studied in healthy people who volunteer to participate in clinical trials.
Apr 20, 2023
0
46
US biotech company Moderna has finalized an agreement to set up a $500 million mRNA vaccine facility in Nairobi, Kenyan President William Ruto said Thursday.
Mar 30, 2023
1
17
An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) ...
Jan 18, 2023
0
4
Silent but deadly. These are words often used to describe cervical cancer—a slow-growing disease that rarely causes symptoms in its early stages.
Jan 5, 2023
0
6
People infected with HIV who receive antiretroviral therapy form antibodies against SARS-CoV-2 after being vaccinated against COVID with mRNA vaccines. Their immune response to the vaccination is, however, less strong than ...
Dec 9, 2022
0
4
There's even more reason to think a vaccine developed against smallpox can help the body fight against mpox (monkeypox virus disease) as well, according to researchers at La Jolla Institute for Immunology (LJI). Their new ...
Dec 7, 2022
0
162
It's thought that for an HIV vaccine to be widely effective, it will have to spur the body to make special antibodies that can neutralize a broad range of HIV strains. Now scientists say they have taken an essential step ...
Dec 2, 2022
0
4
A large team of researchers affiliated with a host of institutions across the U.S., working with two colleagues from Sweden, reports promising results in a phase I clinical trial aimed at testing the efficacy and safety of ...
